← Back to Search

Monoclonal Antibodies

MDX 1411 for Kidney Cancer (MDX1411-01 Trial)

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 38-42 of each cycle
Awards & highlights

MDX1411-01 Trial Summary

To determine the highest and safest tolerated dose of MDX-1411 for the treatment of clear cell renal cell carcinoma (Kidney cancer).

Eligible Conditions
  • Kidney Cancer

MDX1411-01 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of study
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine the maximum tolerated dose of MDX 1411
Determine the safety profile of MDX 1411
Secondary outcome measures
Determine the best overall response rate (BORR)

MDX1411-01 Trial Design

1Treatment groups
Experimental Treatment
Group I: MDX 1411Experimental Treatment1 Intervention
Dose Escalation Cohorts
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MDX 1411
2008
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,652 Previous Clinical Trials
4,130,722 Total Patients Enrolled
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top